The Effect of Food on Lapatinib Bioavailability

When administered with food, lapatinib bioavailability was substantially higher than when given to fasted patients.

The bioavailability of lapatinib (Tykerb) — an oral inhibitor of ErbB1 and ErbB2 tyrosine kinases that is used for HER2-positive breast cancer — is influenced when administered with food. Results of small studies showed that when lapatinib was administered with either a high-fat or low-fat breakfast, the area under the serum-concentration curve (AUC) for the agent was higher (by 60% or 200%, respectively) than when given to patients in a fasted state (Eur J Cancer 2003; 1:S169:abstract 558).

To further characterize the impact of food on lapatinib bioavailability, researchers conducted an industry-supported, crossover study involving 27 patients who had advanced solid breast tumors. Patients received a single dose of lapatinib (1500 mg) on th…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)